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Objectives: As a consequence of Aging society, elderly people have growing need 
for long-term care and special nursing in their own homes as well. The focus of 
Hungarian health care system lacks the examination of health care provisions 
carried out in the social care system. This study aimed to assess the health care 
need within the residential social care institutions. MethOds: In 2015 March-
May - with the support of State Secretary of Social Affairs of the Ministry of Human 
Capacities and the contribution of Hungarian Charity Service of the Order of Malta 
- in 12 residential social care institutions - caring about 600 elderly people - an 
empirical survey was carried out using datasheets focused on care problems and 
health care activities. Data were analysed by descriptive and regression statisti-
cal methods. Further qualitative analysis was carried out making interviews with 
directors of residential care homes. Results: Preliminary results showed that 
average age of inhabitants became increasingly higher (78 years). Growing rate of 
dementia (21.2%), need for intensive care (at least 12-hours a day), or continuous 
monitoring and special nursing (up to 35%) were observed. Our research has been 
continued with detailed analysis of use of special nursing care for the residents 
of social care institutions based on claim and utilization data of the National 
Health Insurance Fund Administration. cOnclusiOns: More and more attention 
should be paid to nursing and other health care activities carried out in social 
care institutions. There is an urgent need for establishment of regulatory back-
ground, specification of human resources, competency level, and creation of incen-
tive system or separate financing. According to our preliminary budget impact 
analysis the normative cover of one site with advanced nursing care costs 500 
THUF, thus yearly 2 billion HUF could cover the operation of 4000 special nursing 
sites.
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Objectives: To overview research methodologies related to external price ref-
erencing (EPR) in order to support an ongoing survey on 1) the comparison of 
European price corridor of pharmaceuticals and non-pharmaceutical services 
and 2) limitations in patient access to drugs in Central Eastern European (CEE) 
countries. MethOds: Comprehensive review of peer reviewed and grey literature 
was conducted in 2015 February. Publications in PubMed database were searched 
using four keyword sets: #1 External reference pricing, #2 Central Eastern Europe, #3 
Consequences, #4 Pharmaceuticals. We used linkage as follows: #1 AND (#2 OR #3 OR 
#4). References from relevant publications and results from manual google search 
were also reviewed. Results: 422 publications were found and abstracts were 
screened by two independent researcher. 38 peer reviewed papers were included 
in the final evaluation. In addition 22 other documents (e.g. working papers by EU, 
WHO or OECD) were also included. EPR has high priority and widely used across 
Europe to price pharmaceuticals. There is an intense but unresolved scientific 
and public debate on choosing between differential pricing vs. narrow price cor-
ridor in Europe. There are several papers on the international price comparison 
of pharmaceuticals, however CEE countries are rarely involved in such studies. 15 
different methodological issues were identified with potentially strong influence 
on research conclusions, including differences in patent status, launch date, price 
category, price level, reimbursement status with or without restrictions in different 
indications, sales volume or confidential discounts. None of the reviewed studies 
took into account all identified issues. No studies with direct comparison of the 
pharmaceutical price corridor to the price corridor of non-pharmaceutical services 
were identified. cOnclusiOns: Methodological issues may heavily influence the 
conclusions of research in international price comparison, and therefore potentially 
bias public opinion on to what extent EPR effects patient access in lower income 
European countries.
PHP148
evaluatIon of fraCtures In tHe elderly In austrIa and drug rIsk 
faCtor analysIs Based on ClaIMs data
Zauner G1, Popper N2, Wilbacher I3
1dwh GmbH, Vienna, Austria, 2University of Technology Vienna, Vienna, Austria, 3Association of 
Austrian Social Insurance Institutions, Vienna, Austria
Objectives: Fractures due to falls are quite often reason for long hospitaliza-
tion and care dependency especially for the elderly. Thus, the reduction of cases 
and complications is of interest for medical insurance companies all over Europe. 
Therefore, the actual status including regional distribution has to be identified and 
drug prescription as one potential risk factor is analysed. MethOds: Claims data 
(GAP-DRG) in the Austrian health care sector is used including many details for 
patient care. GAP-dRG (General Approach for Patient oriented Outpatient-based 
DRG) is a research data base with reimbursement data for outpatient services of 
sickness funds (social insurance) and Federal Ministry of Health (hospital data). 
Based on ICD10 diagnosis subgroups of fracture categories are analysed for the 
years 2001 to 2011. For the 32 health care regions data analysis divided into 5-years 
age group is performed. Data of persons with fracture and without is compared 
regarding their drug use, especially for anticoagulants, psychoanaleptics, urologi-
cals and calcium. RESULTS: In the years 2006 and 2007 over all 63.042 elderly (age 
60+) with a fracture main diagnosis were hospitalized in Austria. The incidences 
vary in the regions and in the 5-years age group. The youngest have an incidence 
rate of less than 10 per 1.000 persons, the old (age 90+) around 50 cases per 1.000 
persons and year. Looking at anticoagulants regional differences in prescription 
are identified, with an average of 80,7 percent, while the non-fracture population 
has only in 60,0 percent at least one prescription in 2006 or 2007 of an anticoagu-
lants. CONCLUSIONS: The realized work represents the actual Austrian situation. 
Additional analysis including longer wash-out phase and detailed analysis of 30-day 
mortality seem promising. Modeling and simulation of regional effects is under 
discussion.
PAS are negotiated on a case by case basis and range from simple discounts to 
more complex arrangements. The objective of this study was to assess the chang-
ing dynamics of PAS within the UK against a background of changing structures 
of healthcare delivery and a greater drive to save costs. MethOds: A search of all 
approved Health Technology Assessments (HTAs) incorporating a PAS for either 
NICE or the SMC between October 2007 and June 2015 was undertaken. In addition, 
numerous sources including structured interviews were analysed to identify the 
key structure and changing dynamics of PAS. Results: 128 HTAs incorporating 
a PAS were approved by NICE or the SMC between October 2007 and June 2015. 
Out of these, 108 consisted of a simple discount on the list price. The remaining 
schemes were more complex in nature and included free stock, dose capping, sin-
gle fixed treatment price, response and rebate schemes. The majority of these PAS 
were incorporated into HTAs approved before August 2011, after which all PAS have 
consisted of a simple discount, with the exception of 3 cases, all of which were 
schemes transferred from earlier submissions for the same product in other indi-
cations. cOnclusiOns: There has been a shift towards simple discount schemes 
in recent years as a preference from both the payer and manufacturer due to easy 
implementation and price confidentiality.
PHP144
early BenefIt assessMent and uPtake of PHarMaCeutICal 
InnovatIons – exPerIenCes froM gerMany 2011 to 2014
Witte J, Greiner W
School of Public Health, Bielefeld University, Bielefeld, Germany
Objectives: In Germany, pharmaceutical manufacturers were free to set prices for 
prescription medicines approved for coverage under the statutory health insurance 
system. However, due to rapidly increasing prices for brand-name drugs and pre-
scribing behavior shifting towards expensive new drugs, Germany enacted legisla-
tion to fundamentally change the way of establishing the value of new drugs and 
using it as the basis for price negotiations. Since 2011, the Pharmaceutical Market 
Restructuring Act (Arzneimittelmarkt-Neuordnungsgesetz – AMNOG) has mandated 
that all newly introduced drugs be subject to an assessment of their benefits in rela-
tion to a comparator, typically the current standard treatment. Yet, market availabil-
ity is formally not affected by assessment results. MethOds: Since January 2011, 
about 130 early benefit assessment procedures have been concluded. For about 100 
products, reimbursement amounts have also been determined. However, the impact 
of the results from the early benefit assessment on doctor’s prescription behavior is 
unknown. Based on prescription data from a large German sickness fund (6.3 million 
assured people) we examined to what extend the uptake of pharmaceutical innova-
tions increase in relation to the amount of additional benefit within twelve months 
after assessment results were published. Results: Our findings indicate that there 
is no correlation of the amount of additional benefit and likelihood of prescription. 
Products with a large benefit (“considerable”) feature a smaller uptake-rate (13%) 
than those with no approved benefit (19%). Medicines with a “minor” benefit show 
an uptake-rate of 18%, whereas those whose benefit is “not quantifiable” show 
the lowest with 7.5%. cOnclusiOns: Multiple interacting factors influencing the 
uptake and diffusion of medicines besides additional benefit considerations. For 
instance, drug characteristics not considered within the benefit assessment that 
might lead to a patient-relevant benefit (such as the way of administration) and 
affect the likelihood of early adoption. Recent examples are given and discussed.
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Objectives: The pharmacies and wholesalers remuneration system in Portugal, 
with drugs dispensing, suffered structural changes after the approval of the 
Memorandum of Understanding (MoU), signed in May 2011 by the Portuguese 
Government and International Authorities, which intensified the degree of public 
pharmaceutical expenditure reduction requirements, in exchange for the financial 
assistance. The objectives of present study were: to provide an overview of these 
changes, its impact for pharmacies (2011-2014) and recent advances towards a more 
comprehensive remuneration system. MethOds: 1) literature review of the pub-
lished legislation and identification of changes; 2) market analysis and pharma-
cies and wholesalers margins were computed using Pharmacy Sales Information 
Systems (SICMED / hmR), two nationwide databases with representative drug dis-
pensing data from ambulatory care (and prescription data); 3) impact of changes and 
implications for the sector and pharmacies. The statistical analysis of the monthly 
data was performed using SAS, Guide 4.1. Results: The fixed linear remunera-
tion system was replaced in January 2012 by a regressive mark-up and minor fees 
system, per ex-factory price range (for pharmacies and wholesalers), determining 
the greatest change to the remuneration system during the last decades. In April 
2014, a fixed fee and a variable mark-up were added in the lowest and highest 
price range. The pharmaceutical market was reduced by 876 million euro and NHS 
expense by 494 million euro over the past four years. The loss of pharmacy and 
wholesaler remuneration was 322.8 Million euro in the same period (37% of the 
overall market reduction), higher to the established objective of 50 million euro in 
the MoU. cOnclusiOns: Changes in the legislation, accentuated after MoU imple-
mentation, caused a large reduction in remuneration of pharmacies, due to directly 
cuts in margins and indirectly decrease in prices. Several studies, published in the 
meantime, support the difficulties for the sector sustainability.
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